NCT04875325View on ClinicalTrials.gov

Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy

NAEnrolling by invitationINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Resectable Pancreatic Ductal AdenocarcinomaRecurrent Pancreatic Ductal Adenocarcinoma
Interventions
OTHER

Standardized surveillance

Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.

Trial Locations (11)

6525 GA

Radboud University Medical Center, Nijmegen

6229 HX

Maastricht UMC, Maastricht

5623 EJ

Catharina Ziekenhuis, Eindhoven

1081 HV

Amsterdam University Medical Center VUmc, Amsterdam

1091 AC

Onze Lieve Vrouwe Gasthuis, Amsterdam

1105 AZ

Amsterdam University Medical Center AMC, Amsterdam

7512 KZ

Medisch Spectrum Twente, Enschede

9713 GZ

University Medical Center Groningen, Groningen

3435 CM

Sint Antonius Ziekenhuis, Nieuwegein

3584 CX

University Medical Center Utrecht, Utrecht

B15 2TT

University of Birmingham, Birmingham

All Listed Sponsors
collaborator

Dutch Pancreatic Cancer Group (DPCG)

UNKNOWN

collaborator

University of Birmingham

OTHER

lead

UMC Utrecht

OTHER